Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Monoclonal Antibody for Patients with Covid-19. Reply

    Research output: Contribution to journalLetterpeer-review

  4. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.

METHODS: In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume.

RESULTS: Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P = 0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P = 0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P = 0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups.

CONCLUSIONS: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).

Original languageEnglish
JournalThe New England journal of medicine
Volume383
Issue number6
Pages (from-to)546-557
Number of pages12
ISSN0028-4793
DOIs
Publication statusPublished - 6 Aug 2020

    Research areas

  • Adult, Antibodies, Monoclonal, Humanized/adverse effects, B-Lymphocytes, Brain/pathology, Crotonates/adverse effects, Disease Progression, Double-Blind Method, Female, Humans, Injections, Subcutaneous/adverse effects, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Relapsing-Remitting/drug therapy, T-Lymphocytes, Toluidines/adverse effects

ID: 61640471